MMP10 Promotes Efficient Thrombolysis After Ischemic Stroke in Mice with Induced Diabetes
Autor: | Carmen Roncal, M. Belzunce, Jose A. Rodriguez, Beatriz Zandio, Manuel Navarro-Oviedo, José A. Páramo, Estefanía Toledo, Agustina Salicio, Obdulia Rabal, Josune Orbe, Roberto Muñoz |
---|---|
Rok vydání: | 2018 |
Předmět: |
Male
0301 basic medicine medicine.medical_treatment Brain damage Pharmacology medicine.disease_cause Brain Ischemia Diabetes Mellitus Experimental Mice Random Allocation 03 medical and health sciences 0302 clinical medicine Fibrinolytic Agents Matrix Metalloproteinase 10 Diabetes mellitus Fibrinolysis medicine Animals Thrombolytic Therapy Stroke business.industry General Neuroscience Thrombolysis medicine.disease Streptozotocin 030104 developmental biology Tissue Plasminogen Activator Administration Intravenous Neurology (clinical) medicine.symptom Cardiology and Cardiovascular Medicine business Plasminogen activator 030217 neurology & neurosurgery Oxidative stress medicine.drug |
Zdroj: | Translational Stroke Research. 10:389-401 |
ISSN: | 1868-601X 1868-4483 |
DOI: | 10.1007/s12975-018-0652-9 |
Popis: | Diabetes is an important risk factor for ischemic stroke (IS). Tissue-type plasminogen activator (tPA) has been associated with less successful revascularization and poor functional outcome in diabetes. We assessed whether a new thrombolytic strategy based on MMP10 was more effective than tPA in a murine IS model of streptozotocin (STZ)-induced diabetes. Wild-type mice were administered a single dose of streptozotocin (STZ) (180 mg/kg) to develop STZ-induced diabetes mellitus. Two weeks later, IS was induced by thrombin injection into the middle cerebral artery and the effect of recombinant MMP10 (6.5 μg/kg), tPA (10 mg/kg) or tPA/MMP10 on brain damage and functional outcome were analysed. Motor activity was assessed using the open field test. Additionally, we studied plasminogen activator inhibitor-1 (PAI-1) and thrombin-antithrombin complex levels (TAT) by ELISA and oxidative stress and blood-brain barrier (BBB) integrity by immunohistochemistry and western blot. MMP10 treatment was more effective at reducing infarct size and neurodegeneration than tPA 24 h and 3 days after IS in diabetic mice. Locomotor activity was impaired by hyperglycemia and ischemic injury, but not by the thrombolytic treatments. Additionally, TAT, oxidative stress and BBB permeability were reduced by MMP10 treatment, whereas brain bleeding or PAI-1 expression did not differ between treatments. Thrombolytic treatment with MMP10 was more effective than tPA at reducing stroke and neurodegeneration in a diabetic murine model of IS, without increasing haemorrhage. Thus, we propose MMP10 as a potential candidate for the clinical treatment of IS in diabetic patients. |
Databáze: | OpenAIRE |
Externí odkaz: |